5:54 PM
Dec 05, 2013
 |  BC Extra  |  Clinical News

Shire reports Phase III dry eye data for lifitegrast

Shire plc (LSE:SHP; NASDAQ:SHPG) reported data on Thursday from the 718-patient Phase III OPUS-2 trial evaluating twice-daily 5% lifitegrast ( SAR 1118) to treat dry eye disease. Lifitegrast met the co-primary endpoint of improving patient-reported eye dryness scores from baseline...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >